Physician profile
Mark A Harrison
NPI 1285799585
$2,301.65
in general payments reported to CMS, 2019-2025
18 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $70.29 · 2021: $19.75 · 2022: $27.72 · 2023: $436 · 2024: $299 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $473.26 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $372.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $251.50 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $217.34 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Astrazeneca Pharmaceuticals Lp | $193.85 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $182.22 | 2021-2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.47 | 2019-2020 | |
| Tactile Systems Technology INC | $85.06 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Janssen Pharmaceuticals, INC | $82.50 | 2019-2024 | Xarelto |
| Bridgebio Pharma, INC. | $69.89 | 2025 | Attruby |
| Boston Scientific Corporation | $68.55 | 2023-2025 | Watchman Flx |
| Pfizer INC. | $47.47 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $32.32 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.62 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.73 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $16.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.